Treatment outcomes of mucosal melanoma of head and neck: Efficacy of immune checkpoint inhibitors for advanced disease
BackgroundHead and neck mucosal melanoma (HNMM) is a rare and aggressive subtype of melanoma. HNMM often develops as a recurrent or metastatic disease, and its prognosis is worse than that of cutaneous melanoma. Recent large-scale clinical studies have reported favorable outcomes with immune checkpo...
Main Authors: | Shusuke Ohshima, Yushi Ueki, Yusuke Yokoyama, Takeshi Takahashi, Ryusuke Shodo, Keisuke Yamazaki, Ryuichi Okabe, Hiroshi Matsuyama, Takafumi Togashi, Sumiko Takatsuka, Tatsuya Takenouchi, Arata Horii |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Surgery |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.1032626/full |
Similar Items
-
Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune‐related adverse events and favorable outcome
by: Yushi Ueki, et al.
Published: (2023-11-01) -
Principles of mucosal immunology /
by: Smith, Phillip D., M.D. 544928, et al.
Published: (2013) -
Chemoradiotherapy with 3-weekly CDDP 80 mg/m2 for head and neck squamous cell carcinoma: 5-year survival data from a phase 2 study
by: Kohei Otaki, et al.
Published: (2022-12-01) -
Mucosal immunity in Toxoplasma gondii infection
by: Schulthess J., et al.
Published: (2008-09-01) -
MORPHOFUNCTIONAL PECULIARITIES OF MUCOSAL IMMUNITY DEPENDING ON METHODS OF OPPORTUNISTIC MICROBIAL INTRODUCTION
by: O. V. Lebedinskaya, et al.
Published: (2012-05-01)